Novo and Pfizer appoint new CFOs while Alnylam sees departure of its chief commercial officer

Novo announced the appointment of a new chief financial officer as part of its effort to improve financial leadership. The hire follows earlier reports that the company is seeking to turn a corner in its strategic direction.

Pfizer also named a new finance chief, signaling a parallel move to strengthen its executive team.

Separately, Alnylam disclosed that its chief commercial officer has left the company amid ongoing challenges, highlighting continued operational difficulties.

These personnel changes reflect a broader focus on leadership adjustments within the biotech and pharma sectors.